论文部分内容阅读
非典型抗精神病药是目前治疗精神分裂症的一线用药。多年来,精神分裂症的治疗目标不仅是控制阳性、阴性症状,还要最终改善患者社会功能。由于受体与药动学的差别,不同非典型抗精神病药物的剂量调整各异。合理调整与优化非典型抗精神病药物的剂量,是保证良好疗效与安全性的基础。非典型抗精神病药帕利哌酮缓释片,采用OROS缓释技术,血药浓度平稳,无需滴定给药,可保持稳定疗效和较少不良反应。帕利哌酮缓释片临床推荐治疗剂量是每日9 mg。
Atypical antipsychotics are currently the first line of treatment for schizophrenia. Over the years, the goal of treating schizophrenia has been to not only control positive and negative symptoms, but ultimately improve the patient’s social functioning. Due to differences in receptor and pharmacokinetics, different atypical antipsychotic dose adjustments vary. Reasonable adjustment and optimization of atypical antipsychotic doses, is to ensure good efficacy and safety of the foundation. The atypical antipsychotic drug Paliperidone sustained-release tablets, OROS sustained release technology, stable plasma concentration, without titration, to maintain a stable effect and fewer adverse reactions. Paliperidone sustained-release tablets clinically recommended therapeutic dose is 9 mg daily.